The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 114-123

  Camargo, Simone M R ^a   Vuille Dit Bille, Raphael N ^a   Mariotta, Luca ^a   Ramadan, Tamara ^a   Huggel, Katja ^a   Singer, Dustin ^a   Götze, Oliver ^b   Verrey, François ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPORTER; BENSERAZIDE; CARBIDOPA; DOPAMINE TRANSPORTER; ENTACAPONE; LEVODOPA; PROTEIN SLC16A10; PROTEIN SLC3A1; PROTEIN SLC3A2; PROTEIN SLC7A8; PROTEIN SLC7A9; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; ANTIPARKINSON AGENT;

ANIMAL EXPERIMENT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG TRANSPORT; FEMALE; INTESTINE ABSORPTION; INTESTINE CELL; KIDNEY EPITHELIUM; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OOCYTE; PARKINSON DISEASE; SEX DIFFERENCE; STRUCTURAL HOMOLOGY; TREATMENT INDICATION; UPREGULATION; WILD TYPE; XENOPUS LAEVIS; ANIMAL; C57BL MOUSE; HUMAN; MDCK CELL LINE; METABOLISM; SMALL INTESTINE; XENOPUS;

AMINO ACID TRANSPORT SYSTEMS, BASIC; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; ANTIPARKINSON AGENTS; DOGS; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; LEVODOPA; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED C57BL; XENOPUS;

EID: 84907179198     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.216317     Document Type: Article

References (60)

1. Ahlskog JE (2011) Cheaper, simpler, and better: tips for treating seniors with Parkinson disease. Mayo Clin Proc 86:1211-1216.
2. Avissar NE, Ryan CK, Ganapathy V, and Sax HC (2001) Na(1)-dependent neutral amino acid transporter ATB(0) is a rabbit epithelial cell brush-border protein. Am J Physiol Cell Physiol 281:C963-C971.
3. Bailey M and Silver R (2014) Sex differences in circadian timing systems: implications for disease. Front Neuroendocrinol 35:111-139.
4. Bauch C, Forster N, Loffing-Cueni D, Summa V, and Verrey F (2003) Functional cooperation of epithelial heteromeric amino acid transporters expressed in Madin-Darby canine kidney cells. J Biol Chem 278:1316-1322.
5. Bertran J, Werner A, Moore ML, Stange G, Markovich D, Biber J, Testar X, Zorzano A, Palacin M, and Murer H (1992) Expression cloning of a cDNA from rabbit kidney cortex that induces a single transport system for cystine and dibasic and neutral amino acids. Proc Natl Acad Sci USA 89:5601-5605.
6. Biber J, Stieger B, Stange G, and Murer H (2007) Isolation of renal proximal tubular brush-border membranes. Nat Protoc 2:1356-1359.
7. Bröer A, Juelich T, Vanslambrouck JM, TietzeN, Solomon PS,Holst J, Bailey CG, Rasko JE, and Bröer S (2011) Impaired nutrient signaling and body weight control in a Na1 neutral amino acid cotransporter (Slc6a19)-deficient mouse. J Biol Chem286:26638-26651.
8. Bröer A, Klingel K, Kowalczuk S, Rasko JE, Cavanaugh J, and Bröer S (2004) Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder. J Biol Chem 279:24467-24476.
9. Bröer S (2008) Apical transporters for neutral amino acids: physiology and pathophysiology. Physiology 23:95-103.
10. Bröer S and Palacín M (2011) The role of amino acid transporters in inherited and acquired diseases. Biochem J 436:193-211.
11. Buijs RM, la Fleur SE, Wortel J, Van Heyningen C, Zuiddam L, Mettenleiter TC, Kalsbeek A, Nagai K, and Niijima A (2003) The suprachiasmatic nucleus balances sympathetic and parasympathetic output to peripheral organs through separate preautonomic neurons. J Comp Neurol 464:36-48.
12. Camargo SM, Makrides V, Virkki LV, Forster IC, and Verrey F (2005) Steady-state kinetic characterization of the mouse B(0)AT1 sodium-dependent neutral amino acid transporter. Pflugers Arch 451:338-348.
13. Camargo SM, Singer D, Makrides V, Huggel K, Pos KM, Wagner CA, Kuba K, Danilczyk U, Skovby F, and Kleta R, et al. (2009) Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with Hartnup mutations. Gastroenterology 136:872-882.
14. Castelló A, Gumá A, Sevilla L, Furriols M, Testar X, Palacín M, and Zorzano A (1995) Regulation of GLUT5 gene expression in rat intestinal mucosa: regional distribution, circadian rhythm, perinatal development and effect of diabetes. Biochem J 309:271-277.
15. Dave MH, Schulz N, Zecevic M, Wagner CA, and Verrey F (2004) Expression of heteromeric amino acid transporters along themurine intestine. J Physiol 558:597-610.
16. Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, Tateno F, Tsuyusaki Y, and Takahashi O (2012) Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. J Neurol Sci 319:86-88.
17. Feliubadaló L, Font M, Purroy J, Rousaud F, Estivill X, Nunes V, Golomb E, Centola M, Aksentijevich I, and Kreiss Y, et al.; International Cystinuria Consortium (1999) Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,1AT) of rBAT. Nat Genet 23:52-57.
18. Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ, and Stern GM (1989) The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 52:1063-1067.
19. Gomes P and Soares-da-Silva P (2002) Na1-independent transporters, LAT-2 and b0,1, exchange L-DOPA with neutral and basic amino acids in two clonal renal cell lines. J Membr Biol 186:63-80.
20. Hickey P and Stacy M (2011) Available and emerging treatments for Parkinson's disease: a review. Drug Des Devel Ther 5:241-254.
21. Hollingworth SA, Rush A, HallWD, and Eadie MJ (2011) Utilization of anti-Parkinson drugs in Australia: 1995-2009. Pharmacoepidemiol Drug Saf 20:450-456.
22. Iñigo C, Barber A, and Lostao MP (2006) Na1 and pH dependence of proline and beta-alanine absorption in rat small intestine. Acta Physiol 186:271-278.
23. Kallio M, Haapaniemi T, Turkka J, Suominen K, Tolonen U, Sotaniemi K, Heikkilä VP, and Myllylä V (2000) Heart rate variability in patients with untreated Parkinson's disease. Eur J Neurol 7:667-672.
24. Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, and Endou H (2001) Expression cloning of a Na1-independent aromatic amino acid transporter with structural similarity to H1/monocarboxylate transporters. J Biol Chem276:17221-17228.
25. Kleta R, Romeo E, Ristic Z, Ohura T, Stuart C, Arcos-Burgos M, Dave MH, Wagner CA, Camargo SR, and Inoue S, et al. (2004) Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet 36:999-1002.
26. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, and ChaseWM, et al. (2002) Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 58:1418-1422.
27. Lennernäs H, Nilsson D, Aquilonius SM, Ahrenstedt O, Knutson L, and Paalzow LK (1993) The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol 35:243-250.
28. Lundqvist C (2007) Continuous levodopa for advanced Parkinson's disease. Neuropsychiatr Dis Treat 3:335-348.
29. Mariotta L, Ramadan T, Singer D, Guetg A, Herzog B, Stoeger C, Palacín M, Lahoutte T, Camargo SM, and Verrey F (2012) T-type amino acid transporter TAT1 (Slc16a10) is essential for extracellular aromatic amino acid homeostasis control. J Physiol 590:6413-6424.
30. Martinelli P, Contin M, Scaglione C, Riva R, Albani F, and Baruzzi A (2003) Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurol Sci 24:192-193.
31. Miller IN and Cronin-Golomb A (2010) Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord 25:2695-2703.
32. Miyauchi S, Abbot EL, Zhuang L, Subramanian R, Ganapathy V, and Thwaites DT (2005) Isolation and function of the amino acid transporter PAT1 (slc36a1) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesicles. Mol Membr Biol 22:549-559.
33. Moret C, Dave MH, Schulz N, Jiang JX, Verrey F, and Wagner CA (2007) Regulation of renal amino acid transporters during metabolic acidosis. Am J Physiol Renal Physiol 292:F555-F566.
34. Morimoto E, Kanai Y, Kim do K, Chairoungdua A, Choi HW, Wempe MF, Anzai N, and Endou H (2008) Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters. J Pharmacol Sci 108:505-516.
35. Nguyen TV, Smith DE, and Fleisher D (2007) PEPT1 enhances the uptake of gabapentin via trans-stimulation of b0,1 exchange. Pharm Res 24:353-360.
36. Nyholm D and Lennernäs H (2008) Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 4:193-203.
37. Nyholm D, Lennernäs H, Johansson A, Estrada M, and Aquilonius SM (2010) Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease. Clin Neuropharmacol 33:181-185.
38. Pácha J and Sumová A (2013) Circadian regulation of epithelial functions in the intestine. Acta Physiol 208:11-24.
39. Palacín M, Estévez R, Bertran J, and Zorzano A (1998) Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev 78:969-1054.
40. Palacín M, Nunes V, Font-Llitjós M, Jiménez-Vidal M, Fort J, Gasol E, Pineda M, Feliubadaló L, Chillarón J, and Zorzano A (2005) The genetics of heteromeric amino acid transporters. Physiology 20:112-124.
41. Pan X and Hussain MM (2009) Clock is important for food and circadian regulation of macronutrient absorption in mice. J Lipid Res 50:1800-1813.
42. Pan X, Terada T, Okuda M, and Inui K (2003) Altered diurnal rhythm of intestinal peptide transporter by fasting and its effects on the pharmacokinetics of ceftibuten. J Pharmacol Exp Ther 307:626-632.
43. Pan X, Terada T, Okuda M, and Inui K (2004) The diurnal rhythm of the intestinal transporters SGLT1 and PEPT1 is regulated by the feeding conditions in rats. J Nutr 134:2211-2215.
44. Pavon JM, Whitson HE, and Okun MS (2010) Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research. Maturitas 65:352-358.
45. Pfeiffer R, Loffing J, Rossier G, Bauch C, Meier C, Eggermann T, Loffing-Cueni D, Kühn LC, and Verrey F (1999) Luminal heterodimeric amino acid transporter defective in cystinuria. Mol Biol Cell 10:4135-4147.
46. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, and Vingerhoets F (2010) Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 5:229-238.
47. Qandeel HG, Duenes JA, Zheng Y, and Sarr MG (2009) Diurnal expression and function of peptide transporter 1 (PEPT1). J Surg Res 156:123-128.
48. Quiñones H, Collazo R, and Moe OW (2004) The dopamine precursor L-dihydroxyphenylalanine is transported by the amino acid transporters rBAT and LAT2 in renal cortex. Am J Physiol Renal Physiol 287:F74-F80.
49. Ramadan T, Camargo SM, Herzog B, Bordin M, Pos KM, and Verrey F (2007) Recycling of aromatic amino acids via TAT1 allows efflux of neutral amino acids via LAT2-4F2hc exchanger. Pflugers Arch 454:507-516.
50. Ramadan T, Camargo SM, Summa V, Hunziker P, Chesnov S, Pos KM, and Verrey F (2006) Basolateral aromatic amino acid transporter TAT1 (Slc16a10) functions as an efflux pathway. J Cell Physiol 206:771-779.
51. Ristic Z, Camargo SM, Romeo E, Bodoy S, Bertran J, Palacin M, Makrides V, Furrer EM, and Verrey F (2006) Neutral amino acid transport mediated by ortholog of imino acid transporter SIT1/SLC6A20 in opossum kidney cells. Am J Physiol Renal Physiol 290:F880-F887.
52. Romeo E, Dave MH, Bacic D, Ristic Z, Camargo SM, Loffing J, Wagner CA, and Verrey F (2006) Luminal kidney and intestine SLC6 amino acid transporters of B0AT-cluster and their tissue distribution in Mus musculus. Am J Physiol Renal Physiol 290: F376-F383.
53. Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F, and Kühn LC (1999) LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem 274:34948-34954.
54. Soares-Da-Silva P, Serrão MP, Pinho MJ, and Bonifácio MJ (2004) Cloning and gene silencing of LAT2, the L-3,4-dihydroxyphenylalanine (L-DOPA) transporter, in pig renal LLC-PK1 epithelial cells. FASEB J 18:1489-1498.
55. Sperandeo MP, Annunziata P, Bozzato A, Piccolo P, Maiuri L, D'Armiento M, Ballabio A, Corso G, Andria G, and Borsani G, et al. (2007) Slc7a7 disruption causes fetal growth retardation by downregulating Igf1 in the mouse model of lysinuric protein intolerance. Am J Physiol Cell Physiol 293:C191-C198.
56. Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, and Frokjaer S (2004) Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci 21:3-16.
57. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, and Endou H (2002) Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 61:729-737.
58. Verrey F, Singer D, Ramadan T, Vuille-dit-Bille RN, Mariotta L, and Camargo SM (2009) Kidney amino acid transport. Pflugers Arch 458:53-60.
59. Wells RG and Hediger MA (1992) Cloning of a rat kidney cDNA that stimulates dibasic and neutral amino acid transport and has sequence similarity to glucosidases. Proc Natl Acad Sci USA 89:5596-5600.
60. Willison LD, Kudo T, Loh DH, Kuljis D, and Colwell CS (2013) Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model. Exp Neurol 243:57-66.